anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: The impact of epigenetic drugs on metastasis and the immunological microenvironment is poorly understood. In this study, we looked at how sirtinol, a SIRT1 inhibitor, affected epithelial-mesenchymal transition (EMT), metastasis, and the immune cells.
MATERIALS AND METHODS: In vitro experiments were carried out using tumor conditioned medium (TCM). For in vivo experiments, sirtinol was administered i.p. in tumor bearing BALB/c mice at a dose of 2 mg/kg body weight either alone or in combination with cisplatin. Estimation of cytokines was carried out using ELISA or ELIspot. Estimation of different markers was done using flow cytometry or western blot.
RESULTS: Sirtinol, a SIRT1 inhibitor, was found to be cytotoxic to 4T1 breast cancer cells with no synergistic effects with cisplatin, both under in vitro and in vivo conditions (p < 0.05). Sirtinol significantly reduced cancer cell metastasis to the spleen which was supported by in vitro findings such as decreased vimentin expression and cell mobility in migration and wound healing assays (p < 0.01). Studies on the effects of 4T1 tumor-conditioned medium on spleen cells indicated changes in T cell proliferation as well as differentiation (p < 0.01). In tumor bearing mice, spleen cells showed elevated IFN-γ secretion, increased CD11b+ cells, and decreased T cells (p < 0.01). This was reversed by sirtinol as well as the combination treatment, which may also have contributed to metastasis inhibition (p < 0.01).
CONCLUSION: Sirtinol, a SIRT1 inhibitor inhibits EMT and metastasis of 4T1 breast cancer cells and also has an impact on the immune microenvironment.
The research will examine the impact of intermittent fasting to promote long term body weight maintenance following successful weight loss in overweight and obese Veterans. This research is especially relevant to the majority of Veterans who struggle with obesity and maintaining weight loss. Obesity increases the risk for storing excess calories in ectopic depots, including skeletal muscle. Intramuscular fat is related to altered substrate utilization (metabolic inflexibility) and defects in insulin sensitivity, ultimately leading to type 2 diabetes mellitus and cardiovascular disease. The objective of this proposal is to test in a randomized clinical trial the effectiveness of an intensive weight management program with and without intermittent fasting (IF) to combat weight regain and the obesity crisis in our Veterans. Further, this application proposes to examine the role of several enzymes involved in skeletal muscle fatty acid oxidation as a mechanism for efficacious long term weight management.
ICC (Intrahepatic CholangioCarcinoma) patients with metastasis has a short survival time and poor prognosis after diagnosis. Treatment methods was few and far from satisfaction. The treatment recommended from NCCN guideline was GEMOX (Systemic Chemotheray) and clinical trials. Our previous study has demonstrate FOLFOX (Systemic Chemotheray based on Oxaliplatin#5- fluorouracil) has a similar survival and tumor response compared with GEMOX. Further study was needed to intensive confirmation of the result. We designed this study to demonstrate the hypothesis. Metastasis ICCs were recruited and screened by our criteria. All patients were treated with FOLFOX (Systemic Chemotheray based on Oxaliplatin#5-fluorouracil ), lenvatinib (one of tyrosine kinase inhibitors) plus sintilimab (one of PD-1 antibody).
Cerebral Palsy can be defined as a non-progressive lesion that occurs in the brain that has not yet completed its development and causes activity limitation with movement and posture problems. Although the disorders seen in Cerebral Palsy are not progressive, these individuals may experience losses in their current motor functions in later ages and this may cause losses in their independence and activities of daily living. The hippotherapy simulator imitates the three-dimensional mechanical movement and walking of the horse and transfers the mechanical effect to the rider during hippotherapy. The aim of this study was to investigate the effect of exercise program with hippotherapy simulator on upper extremity functions and trunk control of individuals with cerebral palsy.All individuals diagnosed with Cerebral Palsy who agree to participate in the study and meet the inclusion criteria will be randomly divided into two groups as Study and Control Group. In addition to conventional physiotherapy, the study group will be trained in the Hippotherapy Simulature for 15 minutes a day, 5 days a week for 4 weeks.n addition to conventional physiotherapy, the control group will be allowed to sit in the Hippotherapy Simulature for 15 minutes a day, 5 days a week for 4 weeks. However, the simulator will be kept in closed position to prevent oscillations.
NEW MATERIAL:A complex of formula I (n is an integer 1-20; m is an integer 1-6; l is an integer 1-6; X is halogen). USE:An oxygen adsorbent. PREPARATION:A carboxylic acid of formula II is reacted with 5,10,15,20-tetra (alpha,alpha,alpha,alpha-o-aminophenyl)porphyrin of formula III in the presence of a base to form a compound, which is then reacted with anhydrous aluminum chloride in the presence of anisole to remove the benzyl group thereform. The resultant compound is further reacted with ferrous bromide in the presence of pyridine and then treated with 48% hydrobromic acid, concentrated hydrochloric acid, etc. to give an intermediate in which bromine ions, chloride ions or iodine ions are coordinated. The intermediate is then reacted with an alpha,omega-dicarboxylic acid anhydride, etc. of formula IV in the presence of a basic catalyst and then with one terminal aminooligoethylene glycol of formula V to afford the aimed complex of formula I .
BACKGROUND: The aim of the Posner-Schlossman Syndrome European Study Group (PSS-ESG) is to acquire a comprehensive dataset of European patients with PSS. Here, we present the first report on the study protocol and the clinical findings of the patients at baseline.
METHODS: The PSS-ESG is a retrospective, multicentre study designed to evaluate patients with PSS. The study, designed and driven by a European Expert Committee includes three datasets: (1) the baseline, (2) the follow-up and (3) the intraocular pressure (IOP)/glaucoma dataset.
RESULTS: A total of 11 centres adhered to the PSS-ESG and 107 patients were included (68 males, 39 females) mostly Caucasian (93.4%). At uveitis onset, the patient's age ranged between 11 and 76 years, (mean age: 42±15 years).Best-corrected visual acuity was >0.5 in 80.3% of the eyes, IOP was >40 mm Hg in 44% of the eyes. Keratic precipitates were found in 78.5% of the eyes. No flare or cells in anterior chamber were detected in 56% and 53% of the cases, respectively. PCR analysis on aqueous sample was positive for cytomegalovirus-DNA in 50.6% out of the 81 tested patients.
CONCLUSIONS: The PSS-ESG is the first multicentre study aimed to collect a comprehensive dataset of patients with PSS in non-Asian countries. A middlde-aged Caucasian male with a low-grade anterior chamber inflammation, keratic precipitates, preserved visual acuity and marked increased in IOP seemed to be the standard PSS patient across the 11 uveitis and glaucoma centres participating in the PSS-ESG.
Chronic kidney disease (CKD) is a worldwide public health problem, with adverse outcomes of kidney failure, cardiovascular disease (CVD), and premature death. Chronic kidney disease (CKD) affects between 8% and 16% of the population worldwide.Defined by a glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m2, albuminuria of at least 30 mg per 24 hours, or markers of kidney damage (eg, hematuria or structural abnormalities such as polycystic or dysplastic kidneys) persisting for more than 3 months.That nutrient loss because of diet restriction and chronic inflammation contributed by CKD itself may stimulate progression in advanced chronic kidney disease. Folic acid was then selected as a nutrient intervention. In the mean time, pentoxifylline was well studied in this field for its anti-inflammatory effects.Pentoxifylline (PTF) appears to improve circulation through its ability to alter erythrocyte deformability and enhances capillary microcirculation. This hemorheological property and the potential capacity in decreasing intraglomerular pressure has led to recent interest in PTF as a therapeutic agent in patients with kidney disease. In addition to these properties, PTF has an effect on inflammation, oxidative stress and endothelial function.
To explore the differences in brain imaging in tinnitus with or without hearing loss (HL). We acquired functional MRI scans from 26 tinnitus patients with HL (tinnitus-HL), 24 tinnitus patients with no HL (tinnitus-NHL), and 26 healthy controls (HCs) matched by age and sex. The left and right thalamus were selected as seeds to study the endogenous functional connectivity (FC) of the whole brain, and its correlation with clinical indices was analyzed. Brain regions showing FC differences among the three groups included the Heschl gyrus (HES), right Hippocampus (HIP), right Amygdala (AMYG), left Calcarine fissure and surrounding cortex (CAL). Post hoc analysis showed that the thalamus-HIP connection and thalamus-lingual gyrus (LING) connection were enhanced in the tinnitus-NHL group, as compared to tinnitus-HL. Compared with HCs, the tinnitus-NHL group showed an enhanced connection between the thalamus and the left Inferior occipital gyrus, left CAL and LING. While in the tinnitus-HL group, the connection between the thalamus and several brain regions (right HES, right AMYG, etc) was weakened. In the tinnitus-HL group, the tinnitus handicap inventory scores were positively correlated with the FC of the left thalamus and right HES, right thalamus and right Rolandic operculum. The duration of tinnitus was negatively correlated with the FC of the right thalamus and right HIP. Abnormal FC in the thalamus may play an important role in the pathogenesis of tinnitus. Tinnitus-NHL and tinnitus-HL show different connection patterns, indicating that there are some differences in their pathogenesis.
Placebo taken by mouth twice daily for 4, 30 day cycles. Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
A system for providing role-based data feeds for a plurality of patient caregivers includes a portable central device and a patient data display screen. The central device is configured to obtain the medical data via one or more sensors and/or electrodes configured to couple to the patient and provide the medical data to mobile devices, optionally as multiple role-based data feeds. The central device may include software and hardware configured to feed the medical data to the mobile devices via multiple role-based data feeds. The patient data display screen is configured to display the medical data. Each mobile device may identify an associated type of medical data by displaying a screen enabling a caregiver to select the associated type of medical data based on their role, or may receive a respective role-based data feed from the central device. Each mobile device is configured to display the received medical data.
PURPOSE:To improve antibacterial activity without causing toxicity, by cultivating a bacterium belonging to the genus Streptomyces capable of producing antibiotic mureidomycin E and F in a medium. CONSTITUTION:Streptomyces flavidovirens strain SANK60486 is aerobically cultivated in a medium containing glucose, peptone, etc. at 20-37 deg.C at pH of about neutrality for 72-96hr to give a culture mixture. Then the culture mixture is purified by centrifugal separation, ion exchange treatment, etc. to produce antibiotic mureidomycin E (properties of substance; amphoteric, water- soluble or white powder; specific rotatory power: [alpha]-D<25>=-34.2 deg.) shown by formula I (X is compound shown by formula II or formula III; R is H, alkyl, alkenyl, alkynyl, aryl or aralkyl), antibiotic mureidomycin F (properties of substance; as shown for antibiotic mureidomycin E; specific rotatory power: [alpha]D<25>=-40.3 deg.), derivative thereof, salt and ester thereof.
This arm includes patients qualified to BPA procedure. They have a baseline workup performed before the initiation of BPA treatment and had a follow up examination from 3 to 6 months after the last BPA session.
NEW MATERIAL:A compound shown by the formula I [R1 is H, halogen, lower alkyl, lower alkoxy or OH; R2 is halogen, lower alkyl, lower alkoxy or OH). EXAMPLE:2-(4-Chlorophenyl)pyrazine. USE:An antithrombotic agent. Since it suppresses extremely thrombosis induced by adenosine 5'-diphosphate or collagen, it is extremely effective against thrombosis caused by thrombosis of myocardial infraction, cerebral thrombosis, etc.; it is usable as a safe drug having weak toxicity. PREPARATION:Ethylenediamine or its salt is blended with a glyoxal derivative shown by the formula II in a solvent such as an alcohol at <= room temperature incorporated with a base such as KOH, etc., and reacted under heating at 50-150 deg.C to give a compound shown by the formula I.
Subjects aged between, and including 12 and 24 months received a single dose of Infanrix-IPV+Hib™. The vaccine was administered intramuscularly in the anterolateral side of the thigh.
A man in his early 30s presented with sudden-onset respiratory distress, haemoptysis and reduced urine output. He was in volume overload with a blood pressure recording of 240/180 mm Hg. Pulmonary renal syndrome was suspected and he was initiated on plasmapheresis, followed by steroid pulse therapy. Chest radiography and the presence of fragmented red cells on the peripheral smear were unexplained. These were later explained by hypertensive nephropathy and thrombotic microangiopathy changes on renal biopsy. His respiratory and haematological parameters improved with blood pressure control. Malignant hypertension closely resembles pulmonary renal syndrome, which must be remembered in order to avoid plasmapheresis and high-dose immunosuppressive therapy.
Methods for expanding regulatory T cells in vitro are provided. It has been discovered that regulatory T cells can be expanded in vitro by culturing a mixed population of lymphocytes on planar cell culture substrates, for example cell culture dishes, coated with binding partners for TCR complex and CD28. Remarkably, culturing mixed populations of lymphocytes on planar substrates coated with anti-CD3 and anti-CD28 antibodies induced apoptosis of effector T cells. It is believe that this is the first cell culture technique that expands regulatory T cells while inducing the apoptosis of effector cells in the mixed lymphocyte population using binding partners for cell surface proteins immobilized on planar substrate. Because effector T cells are typically present in mixed populations of lymphocytes, effector T cells compete with regulatory T cells and typically overtake the cell culture. The disclosed methods decrease the population of effector cells allowing regulatory T cells to expand by at least 100, typically by 400 fold. The resulting cultures of regulatory T cells have less than about 20%, 15%, or 10% of effector T cells.
PURPOSE: To accurately provide a proper dental prosthesis by filling a specific single component polymerizing composition into a mold surrounded by a microwave-transmitting flask, making the mold surround a chamber wall having an outer surface of dental prosthesis, and performing polymerization while keeping a pressure at a predetermined level. CONSTITUTION: After a single component composition 15 containing an initiator and a monomer that can be polymerized by the irradiation of microwave energy is injected to a mold surrounded by a flask 13 made of a microwave-transmitting resin, flask 13 is removed from the injection device, and a pressure ram is inserted into a resin shell 12. Then, polymerization shrinkage is reduced remarkably by keeping the single component composition 15 under a pressure of at least 0.5 MPa. Next, an entire assembly of the flask 13 with a recompression device on its top is placed into a microwave irradiation reactor, and is irradiated with microwave energy for a predetermined period of time. After the microwave polymerization, it is removed from the reactor and cooled at room temperature. The upper and the lower flasks are separated from a plaster mold, and the prosthesis is taken out.
The investigators propose to conduct an initial feasibility study in a sample of patients in treatment for major depression using SMART. The intervention will be weekly group therapy session of SMART for 8 weeks duration. Once enrolled, participants will complete a Structured Clinical Interview for Diagnosis (SCID). The SCID will primarily serve to confirm a diagnosis of Major Depressive Disorder. Each study intervention group (3-4 groups) will be composed of 6-8 research participants per group. There will be no comparison group. The investigators aim to assess adherence with goal of 75% completion of the 8 sessions of SMART and of the homework assignments. Resilience will be measured with the Connor-Davidson resilience scale. Secondary outcomes will include subjective and objective clinical rating scales for major depression.
Nursing homes will be randomized within each pair in two arms "incentive to vaccinate", and "do-nothing". In the arm "incentive to vaccinate", vaccination campaigns will be carried out with face-to-face interviews of nursing home workers in order to achieve more than 80% of vaccination coverage. In the "do-nothing", nursing home workers will be vaccinated as usual.

The main endpoint criterion is all-cause mortality of residents. Population sets will be all residents who will be present at start of the influenza season (-2 weeks) or who will be admitted during the influenza season (+ 2 weeks). Onset and end of influenza season will be given by regional influenza surveillance system. Secondary criteria are hospitalizations of residents, morbidity of nursing home workers. A cost-effectiveness ratio of influenza vaccination will be calculated.
Disclosed is a system and method for assisting in verifying that the right medication is efficiently provided to the right patient, in the right dose, at the right time, and via the right route. The system may be employed for administering an infusion order (702) including a first administration, a medication, and a flow rate. The system includes first, second, and third computers. First computer is designed to receive data identifying the order (702). Second computer provides instructions for preparing the first administration and provides a first schedule for preparation of additional administrations if additional administrations are included in the order. Thi rd computer provides instructions for the first administration and provides an initiation signal indicating the initiation of the first administration to t he patient. Third computer also provides a flow rate modification signal. The modification signal causes the system to determine whether to generate a second schedule. The second computer provides the second schedule.
Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with Ewing sarcoma refractory to prior treatment with at least 3 of the following agents: ifosfamide, etoposide, cyclophosphamide, doxorubicin, or vincristine.
A maximal cycle exercise test with the participants assisted by BiPAP (Servo i, Maquet, Siemens) receiving 10 cmH2O pressure support in addition to oxygen therapy. During the test, breathing pattern, inspiratory flow of the inhalation limb and expiratory flow of the exhalation limb, fractional concentration of inspired CO2 (FiCO2) of the inspiratory line was measured for each breath were recorded.
The active ingredient in Lansoprazole Delayed-Release Orally Disintegrating Tablets is lansoprazole USP, a substituted benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl] methyl] sulfinyl] benzimidazole, a compound that inhibits gastric acid secretion. Its molecular formula is C16H14F3N3O2S with a molecular weight of 369.36. Lansoprazole, USP has the following structure:

Lansoprazole, USP is a white to brownish crystalline powder which melts with decomposition at approximately 166°C. Lansoprazole, USP is freely soluble in dimethylformamide; soluble in methanol; sparingly soluble in ethanol; slightly soluble in ethyl acetate, dichloromethane and acetonitrile; very slightly soluble in ether; and practically insoluble in hexane and water.

Lansoprazole, USP is stable when exposed to light for up to two months. The rate of degradation of the compound in aqueous solution increases with decreasing pH. The degradation half-life of the drug substance in aqueous solution at 25°C is approximately 0.5 hour at pH 5.0 and approximately 18 hours at pH 7.0.

Lansoprazole, USP is supplied in a Delayed-Release Orally Disintegrating Tablet for oral administration.

Lansoprazole Delayed-Release Orally Disintegrating Tablets are available in two dosage strengths: 15 mg and 30 mg of lansoprazole, USP per tablet. Each delayed-release orally disintegrating tablet contains enteric-coated pellets consisting of 15 mg or 30 mg of lansoprazole, USP (active ingredient) and the following inactive ingredients: aspartame*, crospovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium carbonate, magnesium stearate, maize starch, methacrylic acid copolymer type c, microcrystalline cellulose, strawberry flavor (cis-3-hexan-1-ol, cis-3-hexen-1-yl acetate, cis-3-hexenyl butyrate, cis-3-hexenyl hexanoate, ethyl butyrate, ethyl isovalerate, ethyl valerate, ethyl-2-methylbutyrate, gamma-decalactone, hexyl hexanoate, gum arabic, lactose, maltodextrin, methyl cinnamate, triethyl citrate), talc, titanium dioxide, and triethyl citrate.

*Phenylketonurics: Contains Phenylalanine 4.05 mg per 15 mg Tablet and 8.11 mg per 30 mg Tablet.
Nowadays refractory or relapsed leukemia/lymphoma lacks effective treatment. Innovative therapy is urgently required. Chimeric antigen receptor (CAR)-modified T cells have demonstrated great successes in treating even late stage cluster of differentiation antigen 19 (CD19) positive B cell malignancies. To design better CAR T cells, we have developed new CD19 CARs. Preclinical studies have demonstrated effective killing of CD19 target cells. In this study, the CD19 CARs, will be evaluated in CD19 positive leukemia/lymphoma patients. The primary goal is to confirm its adverse effects including cytokine storm response and any other adverse effects. In addition, tumor targeting and disease status after treatment will also be evaluated.